What does Osimertinib treat
Osimertinib is a third-generation EGFR-TKI targeted drug mainly used for the treatment of EGFR mutation positive non-small cell lung cancer (NSCLC), covering adjuvant therapy, systemic therapy for locally advanced and metastatic patients, especially for T790M resistant mutation patients with significant efficacy.
1. Main indications
(1) Adjuvant therapy: Suitable for adult NSCLC patients with confirmed EGFR exon 19 deletion or exon 21 L858R mutation after tumor resection, with continuous treatment for up to 3 years.
(2) Localized late stage treatment: Used for stage III unresectable NSCLC patients who have not progressed after synchronous/sequential platinum based radiotherapy and chemotherapy, requiring EGFR mutation positivity.
(3) First line treatment for metastatic NSCLC with EGFR sensitive mutations (19del/L858R) as the preferred treatment option.
(4) Post resistance treatment: Targeting metastatic NSCLC patients with T790M mutation after progression of EGFR-TKI therapy.
2. Combination therapy plan
(1) Combined with pemetrexed and platinum based chemotherapy, it is suitable for first-line treatment of EGFR mutation positive locally advanced or metastatic NSCLC, and should be continued until disease progression.
3. Mechanism of action
(1) Specifically inhibiting EGFR sensitive mutations (19del/L858R) and drug-resistant mutations (T790M), exerting anti-tumor effects by blocking the tumor cell proliferation signaling pathway.
Disclaimer：《What does Osimertinib treat》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！